Wei Song

Wei Song

Auto-generated profile, based on publicly available information

Wei Song

Cancer Center, the First Hospital of Jilin University, Changchun, China

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2023 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
JLJin Lu
Jin Lu
YYYongsheng Yang
Yongsheng Yang
XLXiangliang Liu
Xiangliang Liu
XCXiao Chen
Xiao Chen
WSWei Song
Wei Song
ZLZefeng Liu
Zefeng Liu
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer most frequently detected at an advanced stage that limits treatment options to systemic chemotherapy, which has provided only marginal positive clinical outcomes. Currently, the first-line chemotherapeutic agent for PDAC is gemcitabine (GEM). However, the chemotherapy resistance to GEM is often overlooked in the clinical treatment of PDAC due to the lack of effective biological markers. Therefore, it is crucial to find new prognostic markers and therapeutic targets for patients with PDAC. In this study, we identified a novel regulatory mechanism in the development of resistance to GEM in PDAC. Here, we report that LINC01134 was significantly upregulated in primary tumors from PDAC patients. In vitro and in vivo functional studies revealed that LINC01134 promotes PDAC resistance to GEM through facilitating stem cell features and modulating the cell cycle. Mechanistically, LINC01134 interactes with tumor suppressor miR-497-5p in PDAC cells. Increased LINC01134 downregulates miR-140-3p to promotes the oncogenic WNT5A expression. Moreover, m6A demethylase FTO participated in the upregulation of LINC01134 by maintaining LINC01134 mRNA stability through YTHDF2. Taken together, the present study suggested FTO-mediated LINC01134 stabilization to promote chemotherapy resistance to GEM through miR-140-3p/WNT5A/WNT pathway in PDAC. Our study identified new prognostic markers and new therapeutic targets for patients with PDAC.

1 January 2007 in DNA Sequence
Verified
Journal Article
Closed access
JPJianlin Pan
Jianlin Pan
XWXiaolin Wang
Xiaolin Wang
WSWei Song
Wei Song
JCJianxiu Chen
Jianxiu Chen
CLCaojun Li
Caojun Li
QZQingshun Zhao
Qingshun Zhao
Myostatin (Mstn), a member of transforming growth factor beta (TGF-beta) superfamily, plays crucial roles in negative regulation of muscle growth. Yellow catfish, Pelteobagrus fulvidraco Richardson, is one of the most important freshwater aquaculture species in China, but little is known about its genes relate to growth. Here we report molecular cloning and expression pattern of Mstn gene in yellow catfish. Our results reveal that yellow catfish Mstn comprises three exons encoding a protein of 393 amino acid residues. Protein sequence alignments show that the Mstn exhibits 94% amino acid identity with other catfish Mstn and 59.3% identity with cattle Mstn, respectively. Moreover, the predicted bioactive form of yellow catfish Mstn shares 100% identity with other catfish and 87.1% identity with cattle Mstn respectively. Employing reverse transcription polymerase chain reaction (RT-PCR) analysis, we demonstrated that the yellow catfish Mstn gene is expressed in a variety of tissues with varied levels.

31 May 2021 in Theoretical and Applied Genetics
Verified
Journal Article
Closed access
PDF file
ZJZou Jianan
Zou Jianan
WLWenjing Li
Wenjing Li
YZYuting Zhang
Yuting Zhang
WSWei Song
Wei Song
HJHaipeng Jiang
Haipeng Jiang
YHYingpeng Han
Yingpeng Han

26 October 2021 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
RBRilan Bai
Rilan Bai
XCXiao Chen
Xiao Chen
WSWei Song
Wei Song
HTHuimin Tian
Huimin Tian
JCJiuwei Cui
Jiuwei Cui